DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on April 29, 2016, reports the cash position of DBV Technologies S.A. as of March 31, 2016. DBV is a clinical-stage specialty biopharmaceutical company focused on developing Viaskin, an epicutaneous immunotherapy (EPIT) platform for treating food allergies and other immune diseases. The company has global headquarters in Montrouge, France, and New York, NY.
Key Financial Metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents (March 31, 2016) | €308.6 million |
| Cash and Cash Equivalents (December 31, 2015) | €323.4 million |
| Outstanding Ordinary Shares (March 31, 2016) | 24,205,129 |
| Revenue, Profit, and Debt | Not provided in this filing |
Material Changes
Cash and cash equivalents decreased by €14.8 million, representing a decline from €323.4 million at the end of 2015 to €308.6 million as of March 31, 2016. The filing does not provide a detailed breakdown of the cash burn rate or specific operational expenditures for the quarter.
Outlook, Risks, and Management Commentary
The company is advancing clinical trials for Viaskin Peanut and Viaskin Milk, with preclinical development ongoing for Viaskin Egg. Management highlights the potential of the EPIT platform for vaccines and other immune diseases. The filing includes standard forward-looking statement disclaimers, noting substantial risks related to R&D uncertainties, clinical trial outcomes, and regulatory approvals. Investors are cautioned that historical results may not predict future performance.
Key Facts for Investor Verification
- Verify the specific operational expenses driving the €14.8 million reduction in cash reserves during Q1 2016.
- Confirm the current status and enrollment numbers for the Viaskin Peanut and Viaskin Milk clinical trials.
- Review the full Annual Report on Form 20-F for detailed revenue, debt, and liquidity metrics not included in this 6-K.
- Monitor upcoming regulatory milestones for the food allergy product candidates.